H G Jorgensen
Overview
Explore the profile of H G Jorgensen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hayatigolkhatmi K, Padroni G, Su W, Fang L, Gomez-Castaneda E, Hsieh Y, et al.
Bioorg Med Chem Lett
. 2019 Aug;
29(18):2622-2625.
PMID: 31378570
Tyrosine kinase inhibitor (TKI) therapy is the standard treatment for chronic phase (CP)-chronic myeloid leukemia (CML), yet patients in blast crisis (BC) phase of CML are unlikely to respond to...
2.
Venkatpurwar V, Rhodes S, Oien K, Elliott M, Tekwe C, Jorgensen H, et al.
Toxicology
. 2015 Feb;
330:9-18.
PMID: 25637670
Biodegradable nanoparticles are being considered more often as drug carriers to address pharmacokinetic/pharmacodynamic issues, yet nano-product safety has not been systematically proven. In this study, haematological, biochemical and histological parameters...
3.
Crawford L, Chan E, Aujay M, Holyoake T, Melo J, Jorgensen H, et al.
Oncogenesis
. 2014 Mar;
3:e90.
PMID: 24590311
The tyrosine kinase inhibitor (TKI) imatinib has transformed the treatment and outlook of chronic myeloid leukemia (CML); however, the development of drug resistance and the persistence of TKI-resistant stem cells...
4.
Allan E, Holyoake T, Craig A, Jorgensen H
Leukemia
. 2011 Apr;
25(6):985-94.
PMID: 21468038
Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAbl-independent drug that can be...
5.
Davies A, Jordanides N, Giannoudis A, Lucas C, Hatziieremia S, Harris R, et al.
Leukemia
. 2009 Aug;
23(11):1999-2006.
PMID: 19710702
Imatinib mesylate and nilotinib are highly effective at eradicating the majority of chronic myeloid leukemia (CML) cells; however, neither agent induces apoptosis of primitive CML CD34(+) cells. One possible explanation...
6.
Allan E, Hamilton A, Hatziieremia S, Zhou P, Jorgensen H, Vigneri P, et al.
Leukemia
. 2009 Jan;
23(5):1006-8.
PMID: 19151780
No abstract available.
7.
Jorgensen H, Holyoake T
Biochem Soc Trans
. 2007 Oct;
35(Pt 5):1347-51.
PMID: 17956348
CML (chronic myeloid leukaemia) is a myeloproliferative disease that originates in an HSC (haemopoietic stem cell) as a result of the t(9;22) translocation, giving rise to the Ph (Philadelphia chromosome)...
8.
Allan E, Holyoake T, Jorgensen H
Leukemia
. 2006 Sep;
20(11):2054-5.
PMID: 17008889
No abstract available.
9.
Jorgensen H, Allan E, Graham S, Godden J, Richmond L, Elliott M, et al.
Leukemia
. 2005 May;
19(7):1184-91.
PMID: 15889158
Recent studies indicate that a rare population of primitive quiescent BCR-ABL(+) cells are innately insensitive to imatinib mesylate (IM) and persist after IM therapy of patients with chronic myeloid leukemia...
10.
Jorgensen H, Allan E, Jiang X, Liakopoulou E, Richmond L, Eaves C, et al.
Leukemia
. 2003 Jul;
17(7):1430-2.
PMID: 12835742
No abstract available.